Work

Transcriptional control of Sost in bone

Year: 2016
Type: review
Abstract: Sclerostin is an osteocyte derived negative regulator of bone formation. A highly specific expression pattern and the exclusive bone phenotype have made Sclerostin an attractive target for therapeutic intervention in treating metabolic bone diseases such as osteoporosis and in facilitating fracture repair. Understanding the molecular mechanisms that regulate Sclerostin transcription is of great interest as it may unveil new avenues for therapeutic approaches. Such studies may also elucidate how various signaling pathways intersect to modulate bone metabolism. Here we review the current understanding of the upstream molecular mechanisms that regulate Sost/SOST transcription, in bone. • Sost is expressed in several mouse tissues: liver, heart, kidney, brain thymus and bone. In bone, Sost is abundantly expressed in osteocytes, however very low levels of Sost have also been detected in osteoblasts, osteoclasts and chondrocytes. • RUNX2 and osteorix (OSX/SP7) activate SOST via the proximal promoter. SOST transcription is also regulated via methylation of is promixal promoter. • PTH, Mef2C and TGFβ regulate Sost expression via the ECR5 distal enhancer element. • IL-1β, IL-6, BMP and TNFα treatment enhance SOST expression. • Hypoxia induces Sost expression via a HIF-1α-dependent mechanism.
Source: Bone
Language: English
Open Access status: hybrid
Estimated APC paid: $3,960
OpenAlex ID: W2534651070
FWCI: 0.452
Cites: 111
Cited by: 84
Related to: 10